Validation of the French Child and Youth Schizophrenia Proneness Instrument SPI-CY for Early Psychosis Risk Detection in Adolescents Aged 12 to 17

What this Trial Is About

Researchers are evaluating the French validation of the Schizophrenia Proneness Instrument for Children and Youth SPI-CY to improve early detection of psychosis risk in adolescents aged 12 to 17. This approach focuses on identifying subtle early symptoms that may predict the later development of psychosis during the prodromal phase. The study aims to assess how reliably clinicians can use the French SPI-CY by comparing ratings between trained clinicians. All participants will undergo the SPI-CY interview conducted by a trained clinician. The study compares the initial clinicians SPI-CY rating with a second clinicians blind rating based on recorded interviews to test inter-rater reliability. Researchers will also explore connections between SPI-CY results and other clinical assessments, including the Comprehensive Assessment of At Risk Mental State CAARMS, Multisensory Hallucination Scale MHASC, Prodromal Questionnaire 16 PQ-16, Perceptual and Cognitive Aberrations PCA, and the Audiograph. Participants will be assessed with the SPI-CY on the first day, followed by secondary assessments within 15 days. The study involves audio-recorded interviews of SPI-CY administration with consent from adolescents and at least one parent. Researchers will use these assessments to measure the consistency of the SPI-CY tool and its relationship to other psychosis risk scales. The study is expected to last until February 2027, with no masking or placebo controls involved.

French Validation of Schizophrenia Proneness Instrument- Child Youth